Prophylactic Ivermectin in COVID 19 Contacts

Effectiveness of Ivermectin in preventing development of symptomatic Covid-19 among primary contacts of newly diagnosed Covid-19 positive patients at a tertiary care hospital in North India - an interventional study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/08/027282

Enrollment

180

Registered

2020-08-20

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Ivermectin 12mg or Ivermectin 36mg single dose orally once only: The study will have two intervention arms. In the intervention Arm 1: 12mg oral Ivermectin will be given to the close

of the newly diagnosed Covid-19 patient within 24 hours of diagnosis. The drug will be given orally and once only (under supervision). In the intervention Arm 2: 36 mg oral Ivermectin will be given

of the newly diagnosed Covid-19 patient within 24 hours of diagnosis. The drug will be given orally and once only (under supervision). Control Intervention1: Two Multivitamin tablets: In the control g

Eligibility

Inclusion criteria

Inclusion criteria: All the family members of a newly diagnosed Covid-19 patient who are - living with the patient in the last 2 weeks, aged between 18 years and 60 years of age, asymptomatic on the day of diagnosis of the index case.

Exclusion criteria

Exclusion criteria: The following will be excluded from the study: 1. Pregnant or lactating women 2. Those with any degree of ARI symptoms or fever. 3. Person with known history of severe hypersensitivity reaction to previous exposure to Ivermectin. 4. People with pre-existng severe medical conditions according to the judgement of the investigators

Design outcomes

Primary

Measure	Time frame
Symptomatic Covid-19 among the study participantsTimepoint: Between 7 and 10 days of Ivermectin intake	—

Secondary

Measure	Time frame
Adverse effects of Ivermectin experienced by the study participantsTimepoint: On the day of Ivermectin intake and between 7 and 10 days of Ivermectin intake	—

Countries

India

Contacts

Public ContactDr Hariom Kumar Solanki

Govt Institute of Medical Sciences

saurabhsrivas@gmail.com

Outcome results